| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Anti-Hair Loss Powders Seripiprant CAS 866460-33-5 Raw Materials Purity Seripiprant |
| CAS | 866460-33-5 |
| Appearance | White to off-white powder |
| Molecular formula | C24H19FN2O3 |
| Molecular Weight | N/A |
| Assay | 99% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
|
What is Setipiprant? Setipiprant is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. |
However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high
levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera
with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited
mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition,
the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh
clinical trials for this new application can be conducted fairly quickly
Anti-Hair Loss Powders Seripiprant CAS 866460-33-5 Raw Materials Purity Seripiprant
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}